Primary and Secondary Elevations of Maxillary Sinuses: a Prospective Clinical Study in the Posterior Maxillary Region
Transalveolar Crest Parietal Sinus Floor Lift and Secondary Lift for Postoperative Improvement of Neonatal Bone Mass in Sinus: a Prospective Clinical Study in the Posterior Maxillary Region
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Qi Liu, Ph.D
- Phone Number: +86 020 62787153
- Email: liuqi0721@smu.edu.cn
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China
- Recruiting
- NanFang Hospital of Sourthern Medical University
-
Contact:
- Qi Liu, Ph.D
- Phone Number: +86 020 62787153
- Email: liuqi0721@smu.edu.cn
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age≥ 18 years old
- If the posterior maxillary tooth is missing for ≥ 3 months, the patient requires implant restoration and the preoperative examination meets the indications for intramaxillary sinus lift
- Can be scanned with radiology equipment before and after surgery
- RBH ≤ 5mm, alveolar ridge width ≥5mm, each implant site is measured on CBCT
- During implant healing, there is no removable restoration at the implant site
- No history of acute or chronic sinusitis disease, no history of maxillary sinus disease, and no history of previous maxillary sinus surgery
- Be willing to sign informed consent and authorization form, and be able to return to the clinic on time
Exclusion Criteria:
- Heavy smokers (10 cigarettes smoked ≥ day)
- Uncontrolled diabetes (glycated hemoglobin >7%), metabolic bone disease, autoimmune disease or other systemic diseases, the body can hardly withstand implant surgery
- Mentally unable, pregnant or pregnant women
- Any history of contraindications or significant impact on dental implant placement, such as bisphosphonate drug use, chemotherapy or immunosuppressants, head and neck radiotherapy, autoimmune disease, and hypertension
- Untreated periodontal disease, endodontics, or other oral diseases
- Bruxism patients
- Previous implant implant failure at the surgical site
- Anatomical changes in the maxillary sinus, such as maxillary sinus septum or mucosal swelling (defined as the mean thickness of the Schneider membrane at the base of the maxillary sinus > 2 mm)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Transalveolar crest parietal maxillary sinus floor secondary lift
In order to achieve minimally invasive surgery (RBH≤5mm) in patients with severe deficiency of residual bone height in the posterior maxillary region and obtain reliable clinical research results, a secondary sinus floor lifting technique combining the advantages of maxillary sinus lift with the low risk of maxillary sinus lift is proposed.
|
Transalveolar crest parietal maxillary sinus floor secondary lift + bone grafting + implant implantation were used body
|
|
Active Comparator: Transalveolar crest parietal maxillary sinus floor lift
Transalveolar crest parietal maxillary sinus floor lift (OSFE) requires a residual bone height of at least 5 mm and implant placement at the same time.
Its advantages are simple operation, shorter surgical time, reduced trauma and reduced postoperative complications, and the concept of minimally invasive implant surgery is reflected in OSFE.
|
Transalveolar crest maxillary sinus floor lift + bone grafting + implant implant is used
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Neonatal bone mass in the sinus
Time Frame: 3, 6, 12 months after implantation
|
The sum of bone mass (ABH) in the apical region and the elevation height (IPL) of the maxillary sinus floor (IPL) was measured by CBCT 3, 6, and 12 months after implantation
|
3, 6, 12 months after implantation
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Remaining alveolar ridge height
Time Frame: Preoperatively, 3, 6, 12 months after implantation
|
CBCT was used to measure the distance from the lowest coronal level of bone-implant contact to the apical level of bone-implant contact with sinus floor cortical bone
|
Preoperatively, 3, 6, 12 months after implantation
|
|
Maxillary sinus floor elevation height
Time Frame: 3, 6, 12 months after implantation
|
3 months, 6 months, and 1 year after implantation, CBCT was used to measure the distance from the root tip of the implant to the cortical line of the sinus floor
|
3, 6, 12 months after implantation
|
|
Peri-implant marginal bone resorption
Time Frame: Preoperatively, 3, 6, 12 months after implantation
|
CBCT was used to measure the difference between marginal bone level and marginal bone level baseline before surgery, 3 months, 6 months, and 1 year after implantation
|
Preoperatively, 3, 6, 12 months after implantation
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- NFEC-2023-358
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.